Classic galactosemia is an autosomal recessive disorder caused by the deficiency of galactose l-phosphate uridyltransferase (GALT). Although the potentially lethal, neonatal hepatotoxic syndrome is prevented by newborn screening and galactose restriction, long-term outcome for older patients with galactosemia remains problematic. After the cloning and sequencing of the GALT gene, more than 130 mutations in the GALT gene have been associated with GALT deficiency; this review relates them to function and clinical Outcome. TWO common mutations, Q188R and K285N, account for more than 70% of G alleles in the white population and are associated with classic galactosemia and impaired GALT function. In the black population, S135L accounts for 62% of the alleles causing galactosemia and is associated with good outcomes. A large 5 kb deletion in the GALT gene is found in Ashkenazim Jews. The Duarte galactosemia variant is caused by N314D. Homozygosity for N314D reduces GALT activity to 50%. When either E203K or a 1721C+T transition (Los Angeles variant) are present in cis with N314D. GALT activity reverts to normal. In this review, we discuss the structural biology of these mutations as they affect both the GALT enzyme and patient outcome.
INTRODUCTION
The conversion of galactose to glucose l-phosphate is highly conserved throughout evolution and involves unique uridyltransfer through the enzyme galactose l-phosphate uridyltransferase (GALT) (EC 2.7.7.12). Deficiency of GALT in humans was described in 1935 as the syndrome, galactosemia.' Evaluation of outcome in patients with galactosemia began in the 1980s and an enigma was revealed by 1990.~-~ Although neonates were screened and treated within days of birth by a galactose-restricted diet, older children had an unexpected poor outcome. Dysfunctions included ovarian f a i l~r e ,~ verbal dyspraxia,' growth and developmental delay^,^ and neurological signs of cortical and extrapyramidal tract im~airrnent.~ Because GALT enzyme structure is conserved through evolution, the human GALT complimentary-DNA (cDNA) could be cloned using probes homologous to known bacterial amino acid sequences. When the cDNA and the gene for GALT were cloned and s e q~e n c e d , '~'~ the fust mutations in the GALT gene were associated with human galacto~emia."'~ By 1990, genotypelphenotype relationships were reported.20 Because the human GALT gene has 46% identity with the amino acid sequence of Escherichia coli and 100% in defined catalytic considerable progress was made in understanding the mechanisms by which mutations altered enzyme function. The normal GALT enzyme exhibits pingpong, bi-bi kinetic~~l-~' which denotes that one domain of the enzyme binds uridine diphosphate (UDP)-glucose to form a GALT enzyme-UDPglucose intermediate. Glucose 1-phosphate is released whereas uridine monophosphate remains bound to GALT. Galactose l-phosphate then binds with the GALT-uridine monophosphate complex to form GALT-UDP-galactose, UDP-galactose is released, and GALT is freed for the next round of reactions (Fig. 1) . Using the E. coli GALT protein ~r~s t a l , 2~~~ specific structures for these unique reactions could be deduced for the human GALT. One site of particular interest is histidine-proline-histidine-cysteine-glutamine at amino acids 184 to 188 in the human GALT protein. This important site resides on a P-sheet at the core of the catalytic site as revealed in its three-dimensional crystal structure. The critical role of histidine at position 186 in catalysis was confirmed from experiments of sitedirected mutagenesis in the equivalent E. coli GALT protein. 24 Because the most common G allele in the white population is an arginine substituted for a glutamine at position 188 (Q188R), the role of glutamine in these catalytic reactions is of considerable interest. Other natural mutations that ablate, partially impair, salvage, or increase GALT activity were reported and are clarifymg the normal strmtural biochemistry of human GALT.
It is thus timely and clinically important to review mutations in the human GALT gene that cause galactosemia. These mutations are summarized and tabulated (Table 1) with specific reference to their prevalence in ethnic groups induded in Table 2 . The methods used to validate GALT variations as causative of galactosemia, and the relationship of these mutations to long-term outcome are discussed.
The Q188R mutation was first reported in 1991 and is the most common mutation among classic galactosemics of white ethnicity occurring with an allele frequency of 70%.'2*'4 When this mutation was expressed initially in monkey COS cells, it yielded = 10% of the wild-type GALT control activity.14 This incorrect observation was caused by endogenous GALT present in the monkey COS cells. The same mutation has no activity in yeast and E. coli expression systems in which endogenous GALT is a b~e n t .~~.~~ Table 1 Nucleotide changes in the human GALT gene Little is known about the biochemical mechanism(~) by which glutamine-188 is essential or how GALT is impaired by the substitution of an arginine for glutamine at this position. By superimposing the human GALT amino acid sequence on the highly homologous three-dimensional crystal structure of the E. coli GALT,24,25 glutamine-188 lies proximal to and in the beta sheet of H i~'~~-P r o '~~-H i s '~~ which initiates a nucleophilic attack in the release of glucose 1-phosphate from UDP-glucose (Fig. 1)F8 This short stretch of amino acids is conserved evolutionarily and is crucial for normal catalytic function of E. coli GALT.
When human GALT cDNA containing the Q188R mutation was expressed in "knockout" yeast cells, no GALT activity was detectedF6 These investigators demonstrated that when a Q188R-GALT monomeric subunit dimerized with a wild-type GALT subunit to form a "heterodimer," the resultant catalytic activity of the heterodimer was less than 50% of when only the wild-type GALT cDNA was expressed. The investigators suggested that the Q188R-GALT subunit exerted a "dominant negative" effect on a wildtype subunit when the two subunits d i m e r i~e d .~~ This observation was the first to address potential interactions between the GALT subunits, but did not explain the essentiality of glutamine-188 or how the Q188R mutation per se inactivated the catalytic function of the mutant enzyme subunits. Others found that patients homozygous for the Q188R mutation had no GALT protein in erythrocytes, leukocytes, or transformed lymphobla~ts.~~ Using site-directed mutagenesis in an E. coli GALT-knockout system, the Q188 residue was found to be crucial for GALT catalysis with normal amounts of proteinF7 Therefore, the pathobiochemical effects of an arginine substituted for glutamine-188 involve both biostability of the GALT protein and its catalytic function.
The S135L mutation is common among the black population with a prevalence of 62% of G alleles.32 It was classified inaccurately as a neutral polymorphism when expressed in COS cells. 15 In the GALTknockout yeast system, S135L GALT activity was 5% of control activity.33 Although no GALT activity was detected in erythrocytes or lymphoblasts from patients homozygous for the S135L mutation, some activity was present in l e~k o c y t e s ?~,~~ Unexpectedly, whole-body oxidation of 13C-galactose to 13C0, was normal?' Thus the S135L missense mutation is the basis for the "Negro variant" of galactosemia first documented three decades ago.3'33P36 One postulated mechanism for the divergence of GALT activity in different organs is that the mutation increases rates of GALT protein degradation in a tissue-specific manner. The requirement of an hydroxyl amino acid at amino acid position 135 may indicate the need for a zinc ion in this loop which is tissue-specific.
Bioinstability of the GALT protein was postulated 20 years ago a*d is an imporiant component in the pathophysiology of gala~tosemia?~ Missense mutations that alter GALT stability include S135L, N314D, R148W, and H3 19Q.16J7832.38 Perhaps the most intensively studied mutation that destabilizes the GALT protein is the Duarte allele, N314D?9 GALT function is reduced by 50% in cells from patients what are homozygous for the N3 14D mutation and has a distinctive shift in its isozyme pattern when analyzed by isoelectric f o c~s i n g .~*~*~ The bioinstability of the N314D mutation has been quantitated in lymphoblastoid cell lines transformed from patients with these mutation^.^^.^^ An opposite charge change by a second mutation corrected this effect on biostability. Using lymphoblastoid cells, a "revertant" rnissense mutation was caused by a lysine substitution for glutamic acid at position 203 (E203K) but only when E203K was in cis with the N314D mutation. This second charge change "rescued" the destabilization effect of the amartate sub~titution.~~ The two mutations lie outside the catalytic region on a loop and an a-helix that contains a metal ion requiring hydrogen bonding to ferrous ion in the E. coli protein. 24 Both the Q188R and N314D were in linkage disequilibrium with a SacI polymorphism site at nucleotide 1391 in intron E of the GALT gene. This SacI polymorphism, caused by a G-+A transition, is linked to the Q188R mutation." The N314D mutation, on the other hand, was found exclusively on chromosomes without the SacI site at nucleotide 1391. It was proposed that the two common mutations, N314D and Q188R, evolved independently on a different chromosomal backgro~nd.~' Different ethnic distributions of missense mutations also support a general theory that mutations causing galactosernia arose after socialization occurred in modern humans (see below).
The Los Angeles (LA) variant of galactosemia consistently yields higher-than-normal levels (121%) of GALT activity in patients' sample^.^^.^^ The LA GALT biochemical phenotype is associated with the N314D mutation and has the same characteristic shift in isozyme pattern, but has enzyme activity significantly greater than that expected for N3 14D alone.43," By sequencing GALT genes with this biochemical phenotype, a C+T transition at nudeotide 1721 (L218L) was found consistently in cis with N314D. LA-variant lymphoblasts have increased GALT abundance, but not GALT mRNA or bioinstability. The TTA leucine codon, caused by this transition (CTAXTA), is rare in the GALT gene. Therefore, the 1721 C+T transition may enhance GALT translation through codon preference." AU of these patients have normal metabolism of galactose and are not at clinical risk.
ETHNIC DISTRIBUTION OF GALT MUTATIONS
There is a unique distribution of common GALT mutations among different ethnic groups ( Table  2 ). The most common classic galactosemic (G) allele is the Q188R mutation (=50% in the galactosemic population). This mutation, although panethnic,
November/December 1998 . Vol. 1 . No.1 is most prevalent among white patients with galactosemia of Western and Northern European ancestry.12,14v20 The K285N mutation is the second most common mutation among white galactosemic patients and is most prevalent among patients in Southern Germany, Croatia, and Austria.I2 This missense mutation is not detected by conventional single-strand conformation polymorphism screening; polymerase chain reaction-based restriction analysis or allele specific oligonucleotides hybridization must be used to screen for this common mutation. The K285N mutation made up 10% of the total non-Q188R mutant alleles in one study of a white galactosemic population. Other common mutations found in the white population were Y209C and L195P (Table 2 ).16 Each of these mutations contributed 8.5% of the non-Q188R mutant allele. The S135L mutation, which has a prevalence of 62% in all G alleles in our black patient popul a t i~n ,~' was found exclusively in this ethnic group. The F171S mutation, which was once thought to be linked to S135L,16 may also be exclusive to black patients with galacto~emia.~~ Our group identified four "unre1ated"Ashkenazim Jewish families whose probands shared the same 5 kb deletion in the GALT gene.46 This mutation produced a naturally occurring knockout cell line which has been useful in exploring alternate pathways for galactose utilizationj6
Although galactosemia is relatively rare in the Asian populations,'" 12 mutations were identified in East Asian patients with galactosernia (Japanese)." Four of them, AC (bp2756), AT (bp2359), R333W, and P325L, were also identified in the American galactosemic population. Four mutations, insG528, V150L, P183T, and H319Q, were found exclusively in Italian patientsj9 The Y323D mutation was found in one Pakistani family.
The Duarte variant (N314D) is found in all populations with a prevalence ranging from 6% to 20% of "normal" GALT alleles.50 Although there are 131 unique changes found in the GALT gene, many of I Diet, Endogenous production 1
Flg. 1 Metabolic pathways for galactose metabolism.
these changes are private mutations (with a frequency of less than 0.5% of G alleles). It is important to note that six mutations (Q188R, S135L, N314D, K285N, L195P,Y209C) account for 87.5% of the mutant alleles in our study of 568 mutations associated with galactosemia (Table 2) . Since relatively few mutations account for the majority of galactosemic alleles, DNA analysis as a "second tier" to population-based newborn screening for galactosemia and heterozygote detection is feasible for public health programs.
GENOlYPEiPHENOTYPE CORRELATION OF GALT MUTATIONS
Reports on clinical outcome of genotyped patients with galactosemia are relatively scarce. The small sample size of investigations and the different criteria used for assessment of outcome has produced conflicting observations. We previously reported the association of poor patient outcome and homozygosity for the Q188R mutation and the association of good outcome with homozygosity for the S135L m~t a t i o n .~~~*~ Others have not found an effect on outcome of the Q188FUQ188R genotype?' Based on patients' residual red cell GALT activity and the rate of decline of galactose 1-phosphate after the initiation of dietary treatment, three patients with the genotypes Q188R/T138M, Q188RIR259W, and Q188WT350A, respectively, manifested milder clinical symptoms in the newborn period than patients who were homozygous for R333W, Q188R. or L195P.52 A good outcome has been associated with the mutations A330V and W316X in two patients?) Patients with GALT genotypes Q212XlQ188R had poor outcomes.54 A patient who is a compound heterozygote for Q188RIE304X with the LA variant is doing well.55 Poor outcome was described in a GIG patient with a genotype of P 1 8 3 T I u n k n o~n .~~ Despite newborn detection and intervention, a teenager homozygous for the 5 kb deletion also had neurological and ovarian problems. In contrast to earlier proposals, these observations indicate that complete GALT deficiency is compatible with a livebirth and mild long-term complication^.'^ The pathogenesis of chronic complications in galactosemia is complex and remains largely unknown. The severity of incurred neonatal problems is probably the most important variable on outcome. Outcoke involves not only the genotype and impairment of GALT, but also epigenetic factors such as the affinity and capacity ofbrher enzymes involved in galactose metabolism (eslactose reductase, palactose oxidase, ~~~-~alactose-4re~imerase, galact&nase). ~n d o~e : nous galactose p r o d~c t i o n~~ and intake of galactose are two other important factors for considerdon (Fig.  2) . It is probable that accumulation of both galactitol and galactose 1-phosphate within cells are combined causes of cellular and organ failure. Decreased availability of UDP-galactose may also result in reduced production of glycolipids and glycoproteins (Fig. 2) . A knockout mouse model has helped in understanding this pathophysiology although rodent models lack aldose reducta~e.~~ The knockout mouse is homozygous for GALT deficiency, it does not get "sick" and females have normal fertility. Because the mouse has less galactose reductase thanprimates, it produces less galactitol. Mouse milk contains only 2% lactose, comiared with 6% in human milk, whch represents an additional dimension and emphasizes environmental effects on outcome. Reduced intake of lactose may explain the relatively smaller accumulation of erythrocyte galactose 1 -phosphate compared with human newborns with ealactosernia. Therefore, environment.
" genotypic changes in GALT, and epigenetic pathways or galactose metabolism all contribute to outcome in galactosemia.
